C reactive protein is the classic acute phase protein in inflammatory reactions. CRP is the most sensitive of the acute phase reactants and its concentration increases rapidly during inflammatory processes. Complexed CRP activates the classical complement pathway. The CRP response frequently precedes clinical symptoms, including fever.
The SuperFlex™ CRP Assay automated on the SuperFlex™ Automated Chemiluminescence Analyzer delivers high-sensitivity and specificity with results in 5 minutes.
- LOB ≤0.05 mg/L, LOD ≤0.1 mg/L, LOQ ≤0.2 mg/L
- Accuracy: determine 2 standardized accuracy references, the relative deviation of the measured values shall be not more than ± 10%
- Linear range: within [0.1-200] ng/mL, the linear correlation coefficient (r) shall be ≥0.990
- Precision: repeatability ≤ 8%, inter-run difference ≤ 10%
Clinical benefits of CRP assays
- CRP assays are used to detect systemic inflammatory processes; to assess treatment of bacterial infections with antibiotics; to detect intrauterine infections with concomitant premature amniorrhexis; to differentiate between active and inactive forms of disease with concurrent infection, e.g. in patients suffering from Systemic lupus erythematosus (SLE) or Colitis ulcerosa; to therapeutically monitor rheumatic disease and assess anti inflammatory therapy; to determine the presence of post operative complications at an early stage, such as infected wounds, thrombosis and pneumonia, and to distinguish between infection and bone marrow rejection. Postoperative monitoring of CRP levels of patients can aid in the recognition of unexpected complications (persisting high or increasing levels).
- Measuring changes in the concentration of CRP provides useful diagnostic information about how acute and how serious a disease is. It also allows judgements about the disease genesis. Persistence of a high serum CRP concentration is usually a grave prognostic sign which generally indicates the presence of an uncontrolled infection.
- Storage temperature：2-8℃
References:
- Gabay, C., & Kushner, I. (1999). Acute-phase proteins and other systemic responses to inflammation. The New England journal of medicine, 340(6), 448–454.
- Libby P, Ridker P M. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. The American journal of medicine, 2004, 116(6): 9-16.
- Pepys M B, Hirschfield G M. C-reactive protein: a critical update. The Journal of clinical investigation, 2003, 111(12): 1805-1812.
- Anderson J L, Carlquist J F, Muhlestein J B, et al. Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. Journal of the American College of Cardiology, 1998, 32(1): 35-41.
- Pearson, T A, .Mensah, G A,.Alexander RW, Anderson JL, Canon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F, Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association. Circulation., 2003;107:499-511.
